+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatocellular Carcinoma: Competitive Landscape to 2026

  • ID: 4720464
  • Report
  • November 2018
  • Region: Global
  • 50 pages
  • GlobalData

FEATURED COMPANIES

  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Jiangsu Hengrui Medicine
  • Merck & Co.
  • MORE
Hepatocellular Carcinoma: Competitive Landscape to 2026

Summary

Hepatocellular Carcinoma (HCC) is the most common type of liver cancer. It is the sixth most common type of cancer, accounts for around 90% of primary liver cancers, and is third most common cause of cancer mortality. Hepatocellular Carcinoma (HCC) is particularly aggressive and has a poor survival rate (five-year survival < 5%) and therefore remains an important public health issue worldwide.

In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure (from crops), liver cirrhosis and hemochromatosis, while in developed countries, factors for development include diabetes, obesity and Non-Alcoholic Steatohepatitis (NASH). For unresectable Hepatocellular Carcinoma (HCC), the standard of care, Bayer’s Nexavar (sorafenib), prolongs survival by just three months, therefore more treatment options are needed.

Currently, the Hepatocellular Carcinoma (HCC) pipeline features 319 products across all stages of clinical development. TKIs and PD1/PDL1 inhibitors remain a key focus of development, and their investigation in combination with each other or with other drug classes is increasing. The early-stage pipeline is dominated by small molecules, but also includes mAbs, vaccines, and gene therapies.

Eli Lilly’s Cyramza (ramucirumab), which has shown a modest but significant survival benefit in Phase III clinical trials, is set to be the first VEGF inhibitor approved for Hepatocellular Carcinoma (HCC) treatment. PD1/PDL1 inhibitors combined with TKIs, CTLA4 inhibitors, or VEGF inhibitors are set to launch across the 8MM (United States, China, Italy, France, Japan, Germany, Spain and United Kingdom) starting from 2021.

"Hepatocellular Carcinoma: Competitive Landscape to 2026", report provides an assessment of the pipeline, clinical, and commercial landscape of HCC. Overall, it is expected that new drug approvals will drive Hepatocellular Carcinoma (HCC) market growth over the next decade (2016-2026).

Scope
  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trial Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HCC market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Jiangsu Hengrui Medicine
  • Merck & Co.
  • MORE
1. Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports

2. Executive Summary
2.1 Key Findings
2.2 Key Events

3. Introduction
3.1 Report Scope
3.2 Disease Overview and Epidemiology

4. Pipeline Assessment
4.1 Pipeline Overview
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Target/MOA
4.4 Drug Review Designations
4.5 Products in Clinical Development

5. Clinical Trial Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in Hepatocellular Carcinoma
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics

6. Commercial Assessment
6.1 LeadingMarketed Products
6.2 Current and Future Players

7. Competitive Landscape Analysis (2016-2026)
7.1 Events Classification Overview
7.2 US
7.3 5EU
7.4 Japan
7.5 China

8. Appendix
8.1 Sources
8.2 Methodology
8.3 Key Events Included in the Analysis
8.4 About the Authors
8.5 About
8.6 Disclaimer
Note: Product cover images may vary from those shown
  • Bayer
  • Eli Lilly
  • Eisai Co.
  • Merck & Co.
  • Bristol-Myers Squibb
  • MedImmune
  • SillaJen Biotherapeutics
  • Exelixis
  • Ipsen
  • F. Hoffmann-La Roche
  • BeiGene
  • Jiangsu Hengrui Medicine
  • Suzhou Zelgen Biopharmaceutical
  • Shenogen Pharma Group
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll